Published in Cancer Weekly, February 14th, 2006
"The primary objective of the current study was to determine the maximum tolerated dose of PTX that could be added daily to RT in patients with NSCLC. The secondary objective was to achieve a plasma concentration of PTX estimated to exert a radiosensitizing effect," investigators in Italy reported.
"Eighteen patients with locally advanced NSCLC were treated. Sixty Gy of RT were given in 2 Gy fractions, 5 days per week. A daily dose of PTX was delivered by 4-h i.v. infusion before RT. The initial dose level of PTX...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.